The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IKT | -46.04% | N/A | N/A | -97% |
| S&P | +12.65% | +91.73% | +13.89% | +82% |
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | -267.7% |
| Gross Margin | -656700.00% | 0.0% |
| Market Cap | $144.97M | 1560.3% |
| Market Cap / Employee | $9.06M | 0.0% |
| Employees | 16 | 100.0% |
| Net Income | -$9.92M | -99.9% |
| EBITDA | -$11.17M | -121.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $77.74M | 2418.8% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.04M | -75.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -84.98% | 33.0% |
| Return On Invested Capital | -70.55% | -33.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.57M | -10.3% |
| Operating Free Cash Flow | -$5.57M | -10.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.84 | -45.72 | 1.60 | 1.69 | 46.21% |
| Price to Sales | 30.16 | 69.88 | 114.59 | 11547341.00 | - |
| Price to Tangible Book Value | 1.84 | -45.72 | 1.60 | 1.69 | 46.21% |
| Enterprise Value to EBITDA | -1.45 | -9.91 | -6.54 | -7.87 | 2827.84% |
| Return on Equity | -270.1% | -52.0% | -79.0% | -97.5% | -34.87% |
| Total Debt | $0.15M | $0.11M | $0.07M | $0.04M | -78.66% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
